The future of nutrition is personal.

Built on biotic science. Guided by Ridli. Delivered daily.

$1.0MRaising
$300KClosed
$700KRemaining

Confidential · November 2026

The problem

Supplements are built for everyone.
That’s the problem.

In our view, one-size-fits-all formulas are why most people never feel a difference, and why they stop.

01

Same formula for every body

Generic stacks ignore goals, sensitivities, and routines.

02

No feedback loop

Nothing changes when life, training, or symptoms change.

03

No relationship after checkout

Brands sell a bottle, then disappear until the next ad.

The wedge works

Holy Cow!™
I can digest dairy again.

“A bowl of cereal doesn’t result in anywhere near the reaction it used to.”

“I’ve noticed higher tolerance for milk and dairy than before.”

✓ Verified customer
From reactive enzyme tablets around dairy meals to one daily probiotic designed to rebuild confidence. A modern alternative to the meal-timed lactase-enzyme model introduced in the 1970s.
Holy Cow! once-daily lactose digestion support, 30 capsules

Holy Cow!™ is a once-daily probiotic for lactose digestion support with occasional dairy; it is not a lactase enzyme. Quotes are from verified customers and reflect individual experience.

Traction

Customers buy, come back, and stay.

5,000+
Direct orders
$180
Customer LTV
+30%
Peak MoM growth
$7.21
Finished-unit cost
~$15
Customer CAC
~12×
LTV / CAC
84%
Retail product margin at $45 retail, before channel costs
4.8★
Average rating across all brands
85%
Customer retention (management estimate)

Operating metrics are management reported. LTV is a company-reported estimate. Retention is a management estimate; cohort and period require reconciliation. Rating is management-reported across all brands.

The science moat

Our edge starts with the strain.

Gut foundation · Commercial lead
B. adolescentis IVS-1

Once-daily lactose digestion support. The focused hero product behind Holy Cow!™ that opens the customer relationship.

Mind foundation · In development
NeuroAlly™ KGA-10

A postbiotic candidate for sleep, mood, and stress propositions, and the basis of our next-brand concept.

Live 2026Holy Cow!™ once-daily lactose digestion support is the commercial starting point.
Next testsHoly Cow! Jr targets Q4 entry, with a family bundle and new formats extending the routine.
Longer-term R&DOnce-daily sleep and stress support capsules alongside planned 2027 gummy formats.

KGA-10 is subject to evidence, clinical, regulatory, IP, supply, and commercial diligence and launch review. Timing reflects management estimates; future formats remain subject to formulation, claims, and launch review. Pediatric suitability requires review.

The platform

Meet Ridli.

An AI nutrition companion that turns a single product into a personal routine. Text-first, with human guidance when needed.

01Text Ridli. Goals, routine, and how you feel.
02Get your monthly pack. Built for you, shipped to you.
03Check in. Feedback shapes next month’s sachet.
Base probiotic bottle+Monthly personalized sachet

Base 30-count probiotic
+ a monthly personalized sachet

9:41●●●
RidliYour AI nutrition companion
SMS

I started with Holy Cow!™. What else can I build on?

Let’s look at your goals and current routine, then explore what may fit alongside your foundational product.

Next month’s pack

  • Base 30-count probiotic
  • Personalized monthly sachet

Reviewed with human guidance when needed.

Sleep’s been rough this week.

Noted. I’ll factor that into next month’s sachet and check in Friday.

Message Ridli

Illustrative conversation. Ridli is not a diagnostic service. Consumer concept available; management reports an existing code foundation, and production readiness requires validation.

How it compounds

One product starts it. Ridli keeps it growing.

01

Start with the hero

A focused gut or mind foundation customers can feel.

02

Ask for more

New goals and questions bring Ridli in.

03

Personalize

Eligible additions, chosen with guidance, in the monthly pack.

04

Check in

Feedback informs the next routine, and the next order.

Every check-in feeds the next month

Higher LTVCustomer history informs retention and the next offer.
Lower CACCreative and channel learning returns to one shared system.
Faster launchesAI agents reuse evidence, formulas, and workflows.
Asset-light expansionOwn the heroes. Qualified partners fulfill complementary ingredients.

Personalization, partner fulfillment, and delivery extensions are proposed architecture, not a verified live integration or a commitment to supply any ingredient. Safety, claims, data consent, catalog availability, and unit economics are launch gates.

Portfolio

One engine. Many brands.

Holy Cow!
Commercial lead

Holy Cow!™

Daily lactose digestion support, growing into a carefully tested family of formats.

Element Longevity Base
Active adults

Element Longevity

Biotic routines for training and everyday movement, via bike and run stores, clubs, and coaches.

Human Strain
Practitioner-first

Human Strain

Strain-specific nutrition for practices and clients, with SMS-first onboarding.

Great Brain Day is a concept subject to evidence, formulation, and launch review. Product images are illustrative packaging.

Go-to-market

Win the wedge. Scale discovery.

Holy Cow!
Short-form videoDTCAmazon
Holy Cow!™

A name built for short-form

A familiar expression and a ready-made creative hook. Creator clips drive discovery; DTC and Amazon handle purchase and replenishment.

Kyan Olshove racing

Kyan Olshove · 2026 Iceman Cometh Pro Men’s Champion · Element community athlete

Element Longevity

Bike + run stores

Specialty-store pilots pair staff education, clubs, and coaches with QR-led AI onboarding.

Human Strain
Human Strain

Practices + practitioners

SMS-first intake, strain education, practitioner review, and private product ordering.

Creator content→Rights-cleared clips→Measured distribution→DTC / Amazon→Ridli-led relationships

Store pilots and practitioner access are proposed; AI and partner workflows are in development; placements and outcomes are not assumed. Athlete experience is not proof of product efficacy or a guarantee of performance. Race result: 9&10 News, Nov. 9, 2026. Photo: Element Longevity.

Four-year financial path

From $204.5K to $18.43M in net revenue.

$204.5K
$2.75M
$7.38M
$18.43M
2026Net revenue
($151.6K) net income / (loss)
10 months actual + 2 forecast
2027Net revenue
($364.4K) net income / (loss)
Forecast
2028Net revenue
$1.07M net income / (loss)
Forecast
2029Net revenue
$6.32M net income / (loss)
Forecast
Nov 2027
First forecast profitable month
2028
First profitable full year
$6.32M
2029 forecast net income

Financial outlook figures are management projections and forward-looking statements, not guarantees. 2026 reflects 10 months of actuals plus 2 months forecast; 2027–2029 are forecasts.

Four-year outcome

Year 4 creates two credible paths to liquidity.

$5M
Executed SAFE valuation cap
$55–74M
Illustrative 2029 value
11–15×
Illustrative value-to-cap ratio
Path A

Sell the platform

A strategic acquirer buys the portfolio, differentiated strain access, clinical evidence, customer data, and AI operating system together.

Path B

Sell a breakout brand

A category winner such as Holy Cow!™ exits independently while R3VY keeps the engine, science base, and remaining portfolio upside.

Strategic buyers are paying for science, trust, and channel reach

GRÜNS
$1.2BReported EV
Unilever · 2026
Thorne
$3.8BAnnounced
P&G · 2026
Nutrafol
~$826MCash purchase, further 67%
Unilever · 2022
Bountiful core brands
$5.75B3.1× net sales
Nestlé Health Science · 2021

The case is not size parity. It is buyer appetite for differentiated, science-led wellness brands with trusted channels.

2029 value and value-to-cap ratio are illustrative and forward-looking. GRÜNS and Thorne values were publicly reported; Unilever did not disclose the GRÜNS purchase price. Nutrafol reflects €811M converted at the ECB reference rate on July 7, 2022, for a further 67% (total ownership 80%). Bountiful from buyer disclosure.

Team

Operators who have already scaled.

Haig Newton

Co-founder & CEO

Haig Newton

Scaled a health-and-wellness startup to $30M in annual revenue. Leads architecture, capital strategy, and AI-native systems.

Nick Perez

Co-founder & CMO

Nick Perez

Growth marketer who has scaled consumer brands to tens of millions in revenue. Leads positioning, acquisition, and growth.

Darren Becket

CXO

Darren Becket

Leads product strategy, scientific translation, supplier relationships, customer experience, and brand development.

Dr. Shekhar Challa

Dr. Shekhar Challa

Lead investor · Board-certified gastroenterologist

The ask

Complete the $1M raise. Fund the next stage.

$1.0M
External target
$300K
Closed
$700K
Remaining

Closed: $200K direct equity + two $50K SAFEs. Separately, $116,167.96 in founder/partner capital brings total funding to $416,167.96.

$50K
Minimum · Post-money SAFE
$200K
Investment · Direct equity purchase

Use of funds · Prior six-month spending mix

34.4%TeamPayroll and people
25.5%Product + inventoryProduct costs and incremental inventory
25.9%Acquisition + channelsPaid media and marketplace / partner fees
14.2%Operations + AI / R&DOverhead, agent / compute, and Kioga development

Use-of-funds percentages reflect the prior six-month spending mix, shown as a guide to how capital is deployed; they are not a commitment for future allocation.

Thank you.

Let’s build the future of personal nutrition.

Built on biotic science. Guided by Ridli. Delivered daily.

Haig Newton

Co-founder & CEO · R3VY

haig@elementlongevity.com

Hero products.
Personal relationships.
One shared platform.

Confidential · Investor discussion · November 2026

Appendix

Notes & disclosures

Confidential. This presentation is for discussion with prospective investors only and is not an offer to sell or a solicitation of an offer to buy securities.

Operating metrics. Direct orders, LTV, CAC, LTV/CAC, peak MoM growth, finished-unit cost, retail product margin, rating, and retention are management reported. LTV is a company-reported estimate. Retention is a management estimate; cohort and period require reconciliation. Margin is at $45 retail before channel costs.

Forward-looking statements. The financial outlook (2026–2029), first profitable month and year, illustrative 2029 value, and value-to-cap ratio are projections and illustrations, not guarantees. 2026 reflects 10 months actual plus 2 months forecast.

Development thesis. New assets, brands, and services are a development thesis, not booked value. NeuroAlly™ KGA-10 remains subject to clinical, regulatory, IP, supply, and commercial diligence. Future formats and timing remain subject to formulation, claims, and launch review; pediatric suitability requires review.

Ridli. Ridli is not a diagnostic service. The consumer concept is available; management reports an existing code foundation, and production readiness and practitioner data isolation require validation. Conversations shown are illustrative.

Personalization and fulfillment. Partner fulfillment and tool-connection layers are proposed architecture, not a verified live integration or a commitment to supply any ingredient. Safety, claims, data consent, catalog availability, and unit economics are launch gates. Prompt and trace value depends on rights, consent, evaluation, and reuse; no standalone valuation is assigned.

Products. Holy Cow!™ is a probiotic, not a lactase enzyme. Customer quotes reflect individual experience. Packaging shown may be illustrative.

Athlete. Athlete experience is not proof of product efficacy or a guarantee of performance. Race result: 9&10 News, Nov. 9, 2026. Photo: Element Longevity.

Comparable transactions. GRÜNS and Thorne values were publicly reported; Unilever did not disclose the GRÜNS purchase price. Nutrafol reflects €811M converted at the ECB reference rate on July 7, 2022; Unilever bought a further 67%, bringing total ownership to 80%. Bountiful comes from buyer disclosure. The valuation case is not size parity.

Use of funds. Percentages reflect the prior six-month spending mix.

© 2026 R3VY. All rights reserved.

01 / 15